Clinical Trials
BCNI Clinical Trials
See our short film which gives one Irish patient's experience on a clinical trial and gives an overview of clinical trials by Prof Michael O'Dwyer of Blood Cancer Newtork Ireland
BCNI carry out early phase clinical trials in cancer care centres in Galway, Cork and Dublin. Clinical trials are designed to develop and test new and improved ways to treat cancer in people; help prevent a return of cancer; and improve comfort and quality of life for people with cancer. Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies. BCNI trials will focus on novel targeted approaches, including immunotherapy.
Please see here for Patient information leaflet -Clinical trials
.jpg)
Clinical trials are designed to develop and test new and improved therapies
New therapies are usually developed and tested in a laboratory. Then they are thoroughly tested in animals. If the early research (the preclinical trials) shows the therapy is safe and effective, a carefully planned and monitored clinical trial of the drug or treatment will then be conducted in people.
Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies.
-
BCNI carry out early phase clinical trials in cancer care centres in strategic geographical locations (Galway, Cork & Dublin) under a single unified structure.
-
BCNI clinical trials take place at St James’s Hospital, Mercy University Hospital, Cork University Hospital, Beaumont hospital and the Mater hospital. This is led by University Hospital Galway, which has well established early phase trial expertise for blood cancers.
-
The cohesive and national structure of the BCNI makes Ireland an attractive place for industry and clinical researchers to carry out their clinical trials. The main advantage of this is that it will provide blood cancer patients in Ireland with easier access to novel experimental drugs and provide them with a very high level of care and attention.
ACTIVE CLINICAL TRIALS
Please see below for our clinical trials that are currently OPEN
Acute Myeloid Leukemia
Study Title |
Patient Population |
BCNI Sites |
ClinicalTrials.gov link for further study info |
Study Contacts |
|---|---|---|---|---|
| GMI-1271-301 - A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia (AML) |
Galway University Hospital NOW RECRUITING |
GMI1271-301 |
GUH: Jessica Walsh +353 (0)91-494099
|
Multiple Myeloma
Study Title |
Patient Population |
BCNI Sites |
ClinicalTrials.gov link for further study info |
Study Contacts |
|---|---|---|---|---|
| CyBorD-DARA Phase Ib study of weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) withDaratumumab (DARA) in transplant eligible patientswith newly diagnosed Multiple Myeloma (MM). “TheCyBorD-DARA study” | Newly Diagnosed Multiple Myeloma |
Opened at Galway University Hospital and Cork University Hospital and Beaumont RECRUITMENT NOW CLOSED
|
CyBorD-Dara |
GUH:PI: Professor Michael O’Dwyer Contact: Jessica Walsh +353(0(91 494099 Cork University Hospital:PI: Professor Mary Cahill Contact:Debra O’Hare+353 (0)21 49 20051 Beaumont:PI: Dr. John Quinn Contact:Tara Kenny +353 (0)18 09 2080
|
Relapsed Non-Hodgkin Lymphoma
Study Title |
Patient Population |
BCNI Sites |
ClinicalTrials.gov link for further study info |
Study Contacts |
|---|---|---|---|---|
| LYMRIT 37-01: A phase I/II study of lutetium (177–Lu) lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma. | Adults with relapsed Non Hodgkin Lymphoma |
Galway University Hospital
|
http://clinicaltrials.gov/ct2/show/NCT01796171?term=Lymrit&rank=2 OPEN TO RECRUITMENT |
Jessica Walsh Galway University Hospital 091-893314 |
UPCOMING CLINICAL TRIALS
Clinical Trials - Previous trials, now closed
BCNI Clinical trials that are now CLOSED
Acute Myeloid Leukemia
Study Title |
Patient Population |
BCNI Sites |
ClinicalTrials.gov link for further study info |
Study Contacts |
|---|---|---|---|---|
| A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia |
|
Galway University Hospital | GMI1271-201 |
GUH: PI Michael O'Dwyer Contact :Jessica Walsh +353(0)91-494099 |
| GMI-1271-230 - A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma |
Relapsed/Refractory Multiple Myeloma |
Galway University Hospital - Now closed Beaumont Hospital-Now closed Cork University Hospital- Now closed |
GMI1271-230 |
GUH: Jessica Walsh +353 (0)91-494099 Beaumont Hospital: Tara Kenny +353 (0)18 09 2080 Cork University Hospital: Contact:Elizabeth Linehan +353 (0)21 49 20052 |
